贝伐珠单抗联合FOLFOX方案优化治疗晚期结肠癌的疗效观察  

Clinical effects of bevacizumab combined with FOLFOX regimen for patients with advanced colon cancer

作　　者：吕瑶[1] 石燕[1] 王治宽[1] 茅慧[1] 戴广海[1] 

机构地区：[1]解放军总医院肿瘤内二科,北京100853

出　　处：《癌症进展》2014年第6期593-596,共4页Oncology Progress

摘　　要：目的探讨贝伐珠单抗联合FOLFOX方案治疗晚期结肠癌的临床疗效。方法 60例晚期结肠癌患者按随机数表法分为两组,FOLFOX方案组30例,贝伐珠单抗联合FOLFOX方案组(联合组)30例。观察治疗5个周期后两组患者的临床疗效、KPS评分、血清肿瘤标志物的浓度以及不良反应。结果联合组的总有效率为43.33%,明显高于FOLFOX组的16.67%,差异具有统计学意义(P<0.05);联合组治疗后的KPS评分(91.50±2.63)高于同组治疗前(72.35±1.58)以及FOLFOX组治疗后的KPS评分(76.39±1.82),差异均具有统计学意义(P<0.05);联合组患者治疗后血清肿瘤标志物CEA和CA242浓度分别为(19.34±7.81)μg/L和(30.11±17.38)U/ml,明显低于FOLFOX组的(32.47±10.81)μg/L和(50.64±10.98)U/ml,两组间差异具有统计学意义(P<0.05);两组患者出现的不良反应情况比较,差异无统计学意义(P>0.05)。结论与FOLFOX方案相比,贝伐珠单抗联合FOLFOX方案治疗晚期结肠癌有较好的疗效。Objective To investigate the clinical effects of bevacizumab combined with FOLFOX regimen for patients with advanced colon cancer. Method Sixty patients with advanced colon cancer were randomized into either FOLFOX group（30 cases） or bevacizumab combined with FOLFOX group（30 cases） according to a random number table method. The clinical effects, KPS scores, serum tumor markers, and toxicities of all patients were observed after five cycles of treatment. Result After treatment, the overall response rate in bevacizumab combined with FOLFOX group（combination group） was significantly higher than that of FOLFOX group（43.33% vs 16.67%,P〈 0.05）; the post-treatment KPS scores were higher than the pre-treatment KPS scores in combination group [（91.50±2.63） vs（72.35 ± 1.58）, P〈 0.05], and it was also higher than the post- treatment KPS scores of FOLFOX group[（91.50±2.63） vs（76.39±1.82）, P〈 0.05], and the differences of which were of statistically significance. The serum tumor markers of combination group after treatment were significantly decreased compared with FOLFOX group [CEA（19.34±7.81） μ g/L vs（32.47±10.81） μ g/L, P〈 0.05; CA242（30.11±17.38）U/m L vs（50.64±10.98）U/m L, P〈 0.05]; and toxicities were similar between both groups（P〈 0.05）. Conclusion Compared with FOLFOX regimen, bevacizumab combined with FOLFOX regimen is superior in respect of clinical outcomes for patients with advanced colon cancer.

关 键 词：晚期结肠癌 贝伐珠单抗 FOLFOX 化疗 

分 类 号：R735.35[医药卫生—肿瘤]